ERBB2 and breast cancer: Meric-Bernstam and colleagues showed promising results about the efficacy of trastuzumab deruxtecan (T-DXd) among 267 patients harboring unresectable or metastatic solid tumors, including BC (15.4%) with human epidermal growth factor receptor 2 (HER2) overexpression [56].